Polar Asset Management Partners’s Calidi Biotherapeutics CLDI Stock Holding History

Polar Asset Management Partners’s Portfolio CLDI Stock Details CLDI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,042	Closed	-$12.8K	–	741
2024 Q2	$12.8K	Hold	1,042	–	–	﹤0.01%	631
2024 Q1	$65.4K	Hold	1,042	–	–	﹤0.01%	551
2023 Q4	$162K	Hold	1,042	–	–	﹤0.01%	497
2023 Q3	$342K	Sell	1,042 -2,398	-70%	-$2.43M	0.01%	517
2023 Q2	$4.33M	Hold	3,440	–	–	0.08%	320
2023 Q1	$4.24M	Hold	3,440	–	–	0.06%	372
2022 Q4	$4.2M	Sell	3,440 -302	-8%	-$362K	0.05%	473
2022 Q3	$4.42M	Sell	3,742 -15,180	-80%	-$18.2M	0.05%	516
2022 Q2	$22.6M	Buy	18,922 +2,422	+15%	+$2.88M	0.26%	76
2022 Q1	$19.6M	Hold	16,500	–	–	0.21%	94
2021 Q4	$19.4M	Buy	+16,500	New	+$19.4M	0.21%	101

Other funds holding CLDI

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

CPR Investments Rochester, Michigan $130M AUM 29.56% 1-Year Est. Return

RWI

Red Wave Investments Dillsburg, Pennsylvania $335M AUM 15.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

DIM

Delta Investment Management San Francisco, California $559M AUM 19.86% 1-Year Est. Return

AMH

Apollo Management Holdings New York $7.6B AUM 23.97% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

EWM

Evermay Wealth Management Arlington, Virginia $902M AUM 14.76% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Polar Asset Management Partners's CLDI Position: Q3 2024 in Review

Polar Asset Management Partners sold out of Calidi Biotherapeutics (CLDI) in Q3 2024, closing a stake of 1,042 shares — an estimated $12.8K sold.

Polar Asset Management Partners first reported a position in CLDI in Q4 2021 and held it in 11 quarters. The position peaked at $22.6M in Q2 2022. 20 funds tracked by Wall St. Rank hold CLDI as of Q3 2024.

Polar Asset Management Partners reported no remaining Calidi Biotherapeutics position as of Q3 2024 after selling out during the quarter.
Polar Asset Management Partners sold 1,042 Calidi Biotherapeutics shares in Q3 2024, an estimated $12.8K.
Polar Asset Management Partners first reported a position in Calidi Biotherapeutics in Q4 2021 and held it in 11 quarters.
Polar Asset Management Partners's Calidi Biotherapeutics position peaked at $22.6M in Q2 2022.
20 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2024.

Based on Polar Asset Management Partners's 13F filing for Q3 2024, filed 14 Nov 2024.